 The main goal of this study is to evaluate the ability of a single administration of tocilizumab to reduce myocardial damage in patients presenting with an acute ST-segment elevation myocardial infarction STEMI. Secondary objectives are to assess the impact of treatment on: i final infarct size, ii left ventricular size and function, iii inflammation, iv extracellular matrix remodeling, v lipid parameters, vi platelet activation and additional pro- and anti-thrombotic parameters, and vii study drug safety and tolerability. 